About Mito LuiXiaPharma
Mito LiuXia Pharma is a biopharmaceutical company. Our mission is to investigate and develop pharmaceutical and nutraceutical therapeutics in order to promote human wellness and strive toward excellent health.
Mitochondria are double-membrane-bound organelles. The most important function of mitochondria is to produce energy which is essential for sustaining life and supporting organ function. In mitochondrial diseases, less energy would be generated, resulting in cell injury and eventually cell death. Mitochondrial dysfunction affects high energy demand organs first, such as brain, nerve, muscle, skin, liver, pancreas, etc. As a result, clinical presentations generally include diabetes, hypertension, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, thyroid dysfunction, psoriasis and skin aging, PCOS, Fibromyalgia, ADD, ADHD, Anxiety/Depression, Headaches/Migraine, and recurrent infections.
It has long been proposed that these diseases could be effectively treated by correcting and revising mitochondrial function. In fact, previous clinical experience did show that a redox cofactor, i.e., coenzyme A (CoA), Coenzyme Q (CoQ), and heme did effectively change the outcomes of some of the above-mentioned medical conditions.
Mito LiuXia Pharma has a proprietary Reducing Agent-based technology and lead compounds that embody the therapeutic strategy of “correcting” or modulating ATP-related mitochondrial functions. The company expects this technology to have a major impact on developing new, novel drugs in pharmaceuticals and nutraceuticals.
Long Island High-Technology Incubator of Stony Brook University
25 Health Science Drive
Mail Box: 410
Stony Brook NY 11790
Phone: (631) 292-9008
Fax: (631) 621-0259
© Mito Liuxa Pharma all rights reserved